Description:Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) that is primarily used for the treatment of acid-related gastrointestinal disorders, such as gastroesophageal reflux disease (GERD). It functions by selectively inhibiting the gastric H+/K+-ATPase enzyme, which plays a crucial role in gastric acid secretion. This mechanism allows for rapid and sustained reduction of gastric acidity. Tegoprazan is characterized by its high potency, quick onset of action, and a favorable pharmacokinetic profile, which includes a relatively long half-life, allowing for once-daily dosing. Additionally, it has been shown to have a lower potential for drug interactions compared to traditional proton pump inhibitors (PPIs). The substance is typically administered orally and is well-tolerated, with a safety profile that includes common side effects associated with acid suppression therapies. Ongoing research continues to explore its efficacy and safety in various populations and conditions, further establishing its role in the management of acid-related disorders.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
